Medical XpressKey Driver of Aggressive Prostate Cancer Identified, Suggesting New Way to Reverse Drug Resistance

⚠️ Early Stage / Preclinical Research

Resistance to androgen receptor (AR)-targeted therapy remains a major challenge in advanced prostate cancer. Investigators at Fred Hutch Cancer Center identified a previously unrecognized role for a specific transfer RNA, tRNA¹Arg(UCU), in regulating whether prostate cancer cells remain AR-dependent and treatment-sensitive or transition to a more aggressive, therapy-resistant state.

Clinical Considerations

• The study evaluated prostate cancer cell lines, mouse models, and patient tumor samples to examine the role of tRNA biology in disease progression.
• Researchers found that tRNA¹Arg(UCU) levels were elevated in AR-dependent tumors and reduced in treatment-resistant, AR-independent disease.
• Across experimental systems, reduced levels of the tRNA were associated with a more aggressive cellular phenotype and decreased reliance on androgen receptor signaling.
• Investigators reported that restoring the tRNA in resistant models shifted cancer cells toward a more AR-dependent state and renewed sensitivity to AR-targeted therapies.
• The findings suggest that translational control mechanisms, rather than genomic alterations alone, may contribute to prostate cancer lineage plasticity and therapeutic resistance.

Practice Applications

• These findings should be viewed as mechanistic and hypothesis-generating rather than clinically actionable.
• The work identifies tRNA biology as a potential area for future biomarker development in prostate cancer.
• Additional research will be needed to determine whether tRNA¹Arg(UCU) measurements can predict treatment response in clinical settings.
• Future therapeutic strategies may explore whether modulation of tRNA-driven pathways can delay or reverse resistance to androgen receptor-directed therapy.